Reversibility of regorafenib effects in hepatocellular carcinoma cells
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reversibility of regorafenib effects in hepatocellular carcinoma cells
Authors
Keywords
Hepatocarcinoma, Regorafenib, Reversibility, Migration, invasion, Growth
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 72, Issue 4, Pages 869-877
Publisher
Springer Nature
Online
2013-08-19
DOI
10.1007/s00280-013-2269-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular mechanisms of sorafenib action in liver cancer cells
- (2012) Melchiorre Cervello et al. CELL CYCLE
- Paxillin phosphorylation by JNK and p38 is required for NFAT activation
- (2012) Yu-Chi Lee et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Regorafenib for cancer
- (2012) Dirk Strumberg et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
- (2012) Taiga Otsuka et al. HEPATOLOGY RESEARCH
- Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: Growth inhibition, quiescence, and recovery
- (2012) Brian I. Carr et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Effects of low concentrations of Regorafenib and Sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro
- (2012) Brian I. Carr et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: Recommendations from a European nursing task group
- (2011) Kim Edmonds et al. European Journal of Oncology Nursing
- The role of JNK in the development of hepatocellular carcinoma
- (2011) Madhumita Das et al. GENES & DEVELOPMENT
- Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
- (2010) K H T Paraiso et al. BRITISH JOURNAL OF CANCER
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo
- (2010) Gang Wei et al. INTERNATIONAL JOURNAL OF CANCER
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Inhibition of JNK1 expression decreases migration and invasion of mouse hepatocellular carcinoma cell line in vitro
- (2010) Yu Hong Zhang et al. MEDICAL ONCOLOGY
- Reversibility of capillary density after discontinuation of bevacizumab treatment
- (2009) N. Steeghs et al. ANNALS OF ONCOLOGY
- Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines
- (2009) Ju-Hwa Kim et al. BIOCHEMICAL PHARMACOLOGY
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started